Monday, May 20, 2024 9:54:48 PM
UNCY has completed their final pivotal trial and is processing that data ...due to be released in the next 2-4 weeks .
If the trial succeeds their drug OLC will be on the market by end of 2025
Kiwi
If the trial succeeds their drug OLC will be on the market by end of 2025
Kiwi
Recent ARDX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/26/2026 08:16:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:18:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:17:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:14:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:12:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:10:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 12:04:58 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/19/2026 11:39:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/19/2026 11:18:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/19/2026 10:56:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/19/2026 10:28:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/19/2026 08:32:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/19/2026 08:27:44 PM
- Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 • GlobeNewswire Inc. • 05/19/2026 12:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 03:23:54 PM
- Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings • GlobeNewswire Inc. • 05/07/2026 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:02:43 PM
- Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/30/2026 08:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 08:03:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:01:36 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:05:05 PM
- Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings • GlobeNewswire Inc. • 04/27/2026 12:01:00 PM
- Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 • GlobeNewswire Inc. • 04/23/2026 12:01:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 08:04:27 PM
- Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
